Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
Center for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy & Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Microbiol Spectr. 2024 Oct 3;12(10):e0105524. doi: 10.1128/spectrum.01055-24. Epub 2024 Sep 9.
Leishmaniasis is a rare disease in the United States, with an estimated annual incidence of dozens of cases occurring primarily in travelers, migrants, and military personnel. True disease incidence is unknown, since leishmaniasis is not a nationally notifiable condition. Here, we describe the results of molecular leishmaniasis over a 1-year interval (September 2021 to August 2022) when our laboratory served as the primary national reference laboratory for molecular diagnosis of civilian leishmaniasis. We tested 218 specimens submitted from 36 states yielding 94 of the 186 (50.5%) positive cases with species or species complex-level identification and 18 novel mini-exon alleles. Most species belonged to subgenus (75.6%) and associated with cutaneous or mucocutaneous disease. Cases were associated with recent travel (18.1%), travel timing unspecified (7.4%), migration (7.4%), remote travel (2.1%), military (1.1%), or unknown history (63.8%). These data illustrate the clinical utility of molecular testing for leishmaniasis and provide unique insight into disease epidemiology.
Leishmaniasis is a disfiguring, neglected parasitic infection endemic to the Southern United States and the Americas. Despite significant populations at risk-travelers, military and foreign service members, and migrating persons-the epidemiology of the disease in the United States is poorly understood. Moreover, few clinical laboratories in the United States can test for the disease. Here, we present results from 1 year of testing for this disease at a major reference laboratory. These findings are particularly relevant because they coincide with a temporary "pause" on all clinical testing at the CDC. Our findings suggest at least several hundred cases occur each year in the United States. In particular, mucosal leishmaniasis may be more common than previously reported. We also highlight greater genetic diversity in species endemic to the Americas than has been previously sampled, with implications for diagnostic specificity.
利什曼病在美国是一种罕见疾病,估计每年有几十例病例,主要发生在旅行者、移民和军人中。由于利什曼病不是国家法定报告的疾病,因此实际发病率尚不清楚。在这里,我们描述了在一年时间内(2021 年 9 月至 2022 年 8 月)分子利什曼病的检测结果,在此期间,我们的实验室作为民用利什曼病分子诊断的主要国家参考实验室。我们测试了来自 36 个州的 218 个标本,其中 94 个(50.5%)呈阳性,有物种或种复合体级别的鉴定,以及 18 个新的小外显子等位基因。大多数物种属于亚属(75.6%),与皮肤或粘膜疾病有关。病例与近期旅行(18.1%)、旅行时间未指定(7.4%)、移民(7.4%)、远程旅行(2.1%)、军事(1.1%)或不明病史(63.8%)有关。这些数据说明了分子检测在利什曼病中的临床应用,并提供了对疾病流行病学的独特见解。
利什曼病是一种令人毁容的、被忽视的寄生虫感染,流行于美国南部和美洲。尽管有大量处于危险之中的人群——旅行者、军人和外交人员以及移民——但美国对该疾病的流行病学了解甚少。此外,美国很少有临床实验室可以进行这种疾病的检测。在这里,我们展示了一家主要参考实验室在一年时间内对这种疾病的检测结果。这些发现特别重要,因为它们与疾病预防控制中心暂停所有临床检测同时发生。我们的发现表明,美国每年至少有几百例病例发生。特别是,粘膜利什曼病的发病率可能比以前报告的要高。我们还强调了美洲地方物种的遗传多样性比以前采样的要高,这对诊断特异性有影响。